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Bis(N-picolinamido)cobalt(II) Complexes Display Antifungal
Activity toward Candida albicans and Aspergillus fumigatus
Laura H. D. Ghandhi,[a] Stefan Bidula,[c] Christopher M. Pask,[a] Rianne M. Lord,*[b] and
Patrick C. McGowan*[a]
This report highlights the synthesis and characterization of ten
new bis(N-picolinamido)cobalt(II) complexes of the type
[(L)2CoX2]
0/2+, whereby L=N-picolinamide ligand and X=diiso-
thiocyanato (  NCS), dichlorido (  Cl) or diaqua (  OH2) ligands.
Single crystal X-ray (SC-XRD) analysis for nine of the structures
are reported and confirm the picolinamide ligand is bound to
the Co(II) center through a neutral N,O binding mode. With the
addition of powder X-ray diffraction (PXRD), we have confirmed
the cis and trans ligand arrangements of each complex. All
complexes were screened against several fungal species and
show increased antifungal activity. Notably, these complexes
had significant activity against strains of Candida albicans and
Aspergillus fumigatus, with several compounds exhibiting
growth inhibition of >80%, and onecompound inhibiting
Aspergillus fumigatus hyphal growth by >90%. Conversely, no
antifungal activity was exhibited toward Cryptococcus neofor-
mans and no cytotoxicity towards mammalian cell lines.
Introduction
It is estimated that >1.5 million deaths can be attributed to
fungal infections annually.[1] The incidence of fungal infections
is increasing and these infections are often associated with
significant mortality rates in excess of 40%, even with optimal
treatment.[1,2] This is partly due to the increased number of
patients with HIV, those undergoing hematopoietic or whole
organ transplantation, or receiving aggressive chemotherapy,
for which opportunistic fungal or bacterial infections are
particularly worrisome.[3] The recent emergence of naturally
drug resistant species, such as Candida auris and Lomentospora
prolificans, or acquisition of drug resistance in the common
fungal pathogens Candida albicans (C. albicans), Cryptococcus
neoformans (C. neoformans) and Aspergillus fumigatus (A.
fumigatus) only seeks to worsen the prognosis.[4-7] In the USA, C.
albicans is now the fourth most common iatrogenic blood-
stream infection[8] and in developing healthcare systems,
infection with Cryptococcus spp. causes more deaths in HIV
patients than tuberculosis.[9] Furthermore, inhalation of fungi
from Aspergillus spp. cause pathology in >14 million people
and >200,000 deaths annually.[1] There are currently only four
main classes of antifungal drugs routinely utilized in the clinic:
polyenes, azoles, allylamines and echinocandins. Thus, there is a
crucial requirement for the development of new antifungal
drugs.[3]
Despite the requirement for new antifungal drugs, there has
been relatively little investigation into the potential of organo-
metallic or coordination complexes to treat fungal infections.
The nature of the metal ion, the geometry, oxidation states,
hydrophobicity, and surrounding ligand environments all play
an important role in improving the complex’s activity. More-
over, it is well-documented that the steric properties of the
binding ligands effect the drugs pharmacokinetic properties.[10]
Therefore, the antimicrobial properties of metal complexes
cannot be ascribed to chelation alone, and is a balance of
several other contributions.
To date, few reports have been published which exclusively
examine the antifungal activity of cobalt complexes. Cobalt
plays a significant role in biological processes, as it is essential
for metabolism, formation of red blood cells, maintenance of
normal brain and nerve function and importantly it is found in
vitamin B12.[11] The latter contains a cobalt centre in the +1
oxidation state, however, synthetically, this metal is more
commonly found in the +2 and +3 oxidation states. The first
biological assays of cobalt were conducted in 1952 by Dwyer
and co-workers,[12] and over the last decade there has been a
surge in interest of cobalt coordination complexes as
anticancer,[11,13–16] antimalarial,[17,18] antibacterial[19,20] and antifun-
gal agents.[21,22,22–26] In particular, 1,10-bis(salicylideneamino)-4,7-
dithiadecane cobalt(III) iodide (Figure 1A) was screened in mice
and exhibited low systemic toxicity (LD50=75 mgkg
  1), bacter-
iostatic and bactericidal activity against Escherichia coli (E. Coli)
and Staphylococcus haemolyticus (μM range).[12] Dwyer and co-
workers went on to screen a range of active Co(II) complexes
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containing phenanthroline ligands, which have been further
adapted by several other research groups. All have highlighted
complexes with moderate to good antimicrobial activity (e.g.
Figure 1B).[21,27,28] Schiff-base complexes with salan ligands (e.g.
Figure 1C),[22,29] amino acids (e.g. Figure 1D),[30] and benzoic
acids (e.g. Figure 1E),[31] have also shown promising activity
against a range of fungal species, with the majority of this
research being conducted by Chohan and co-workers.[23,24,30,32–34]
Other ligands which have been investigated, include; azoles,[32]
cephalexins,[23] sulfonamides,[33] dithiones,[34] and thiolenes,[24]
with complexes exhibiting a wide range of antimicrobial
activities when bound to other transition metals.
In 2012, Sathyadevi and co-workers studied two Co(II)-
hydrazone complexes (Figure 1F, R=phenyl (1F-a) or thiophen-
yl (1F-b)),[25] and reported that both complexes interact with
Bovine Serum Albumin (BSA), with binding constants of 6.5×
104 M  1 (1F-a) and 3.4×105 M  1 (1F-b), and the complexes
display the ability to scavenge hydroxyl radicals. Additionally,
these complexes were able to scavenge nitric oxide radicals,
with antioxidant activity of the complexes ~5.8× higher than
the free ligand. Importantly, they demonstrated a greater
capacity to prevent oxidation deterioration of lipids (important
in human diseases[35]), and exhibited significant antibacterial
and antifungal activities against a range of bacterial and fungal
species.
To date, the antifungal properties of bis(N-picolinamido)
cobalt(II) complexes have not yet been investigated, with
previous literature only reporting the structural compositions of
the complexes. The first study, in 1984, was conducted by
Tsintsadze and co-workers on [(L)2Co(H2O)2][(CH3COO)2] (Fig-
ure 1G, L=C5H4NC(O)NH2), in which they investigated how the
position of the amide group from the pyridine ring influences
the structure of the corresponding metal complexes.[36] Struc-
tural data shows the dicationic octahedral Co(II) complex has
two picolinamide ligands bound to the metal in a neutral N,O
fashion, with two aqua ligands in a trans arrangement. Further
studies with chloride or squarate acting as the counter-ion
confirmed this trans geometry.[37,38] The corresponding Ni(II) and
Zn(II) aqua complexes also display a trans geometry.[39] Upon
changing the axial aqua ligands to thiocyanate, a neutral cobalt
complex is formed and the geometry switches to a cis arrange-
ment, with the pyridyl rings remaining trans to one another.[40]
Density functional theory (DFT) calculations found that the
lowest energy form of these complexes involves the picolina-
mide ligands in the cis geometry and the isothiocyanate ligands
coordinating through the nitrogen (  N=C=S), as opposed to
the sulfur atom (thiocyanato,   S  C�N). The corresponding
Ni(II) and Zn(II) isothiocyanato complexes also display the same
cis geometry,[23] however, the analogous Cu(II) complex contains
the two ligands in a trans arrangement and coordinated to the
through the sulfur atom. Generally, these types of bis(N-
picolinamido)metal complexes can exist as different isomers
(Figure 2), with the cis(X,X)-trans(N,N)-cis(O,O) and cis(X,X)-cis
(N,N)-trans(O,O) (where X can be any one electron or two
electron ligand; the latter changing the formal charge of the
complex) also existing as enantiomers. Therefore, it is important
to identify the isomers, so their therapeutic activities can be
correctly determined, however, this has not yet been reported
for bis(N-picolinamido)cobalt(II) complexes.
Figure 1. A range of cobalt complexes exhibiting anti-microbial activity.
Figure 2. Potential isomers of [(L)2CoX2] (where L=a picolinamide ligand
and X=any one electron ligand), with the cis/trans descriptors designated in
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Herein we report the synthesis and evaluation of a library of
new bis(N-picolinamido)cobalt(II) complexes. The picolinamide
ligands coordinate in a neutral N,O mode to the cobalt metal
center and theX ligands (X=diisothiocyanato, dichlorido or
diaqua) exist in either a cis or trans arrangement, which was
confirmed by single crystal X-ray diffraction (SC-XRD). This
technique also confirmed that in all cases, the isothiocyanato
ligand is bound to the central cobalt through the nitrogen.
Additionally, the cytotoxicity of all complexes has been
determined through screening against a range of human cell
lines, bacterial species and fungal species.
Results and Discussion
Synthesis of Co(II) complexes: The N-picolinamide ligands were
synthesized via a known literature procedure from the con-
densation of picolinic acid with a functionalized aniline.[41] All
ligands have been previously reported and 1H NMR was used to
confirm successful synthesis.[42–50] The bis(N-picolinamido)cobalt
(II) diisothiocyanato complexes, [(L)2Co(NCS)2] 1–8, were synthe-
sized by the heating (15 mins) of cobalt(II) nitrate hexahydrate
(1 eq.) with a functionalized N-picolinamide ligand (L, 2 eq.),
followed by stirring with potassium thiocyanate (2 eq.) at room
temperature for 2 h. All complexes were isolated as pink-purple
precipitates in moderate to good yields (44–98%,
Scheme 1a).[40] The Co-dichlorido analogue, complex 9, was
prepared by heating/stirring cobalt(II) chloride (1 eq.) with a
functionalized picolinamide ligand (2 eq.) for 2 h, to yield a pale
orange precipitate (98%, Scheme 1b). The synthesis of the
dichlorido analogue was only successful when no electron
withdrawing groups were present on the aryl ring of the ligand,
and this may be explained by the increased acidity of the amide
proton when electron withdrawing groups are present, hence
hindering the N,O coordination to the metal center. Further-
more, the dichlorido analogue was reacted with potassium
iodide (2 eq.) and heated/stirred for 2 h, to form the dicationic
Co-diaqua complex 10 as an orange precipitate (97%, Sche-
me 1c).
All complexes exhibited broad 1H NMR spectra due to the
paramagnetic nature of the complexes (Co(II), d7), however the
positioning of the peaks remains unchanged compared to the
free ligands allowing successful assignment. The IR spectra of
complexes show a broad NH stretch at 3200–3300 cm  1, a
strong isothiocyanato CN stretch at 2070–2100 cm  1 (1–8) and
a strong CO stretch at 1610–1635 cm  1, and these peaks are
shifted to lower wavenumbers when compared to the free
ligands. The appearance of the CN stretch is characteristic of
the formation of diisothiocyanato complexes and was used to
confirm successful synthesis. The UV-vis spectra show intense
ligand-based π-π* absorbance at ~200 nm, less intense charge-
transfer bands between 220–280 nm and weak d–d transitions
at ~640 nm (e.g. Figure S2).
Single-crystal X-ray diffraction (SC-XRD). Single crystals
suitable for SC-XRD analysis were obtained for complexes 1, 2,
4–10 (Table S1–S2, CSD: 2065375–2065383) via slow evapora-
tion of the reaction solvent. The molecular structures for these
complexes are presented in Figure 3, with selected bond
lengths and angles presented in Table 1 and Table S3, respec-
tively. Single pink-purple crystals were obtained for diisothio-
cyanato complexes 1, 2 and 4–8, with solutions performed in
either a triclinic (P-1: 1, 5 and 7) or monoclinic (P21/c: 2 and 4,
Cc: 6 and 8) cell. On changing the ancillary diisothiocyanato
ligands to either dichlorido (9) or di-aqua (10), single orange
crystals were obtained, with structural solutions performed in a
monoclinic (P21/c) cell. The crystal structures confirm that the
two picolinamide ligands coordinate through the pyridyl nitro-
gen and amide oxygen, acting as neutral N,O ligand.[36,37,40] The
axial isothiocyanato ligands coordinate to the Co(II) center
through the nitrogen atom, as opposed to through the sulfur
atom, and this result is consistent with the previous complexes
and DFT calculations performed by Đaković and co-workers.[40]
The Co  N(pyridyl) bond lengths are in the range
2.0887(18)–2.141(3) Å and the Co  O(amide) bond lengths are in
the range 2.0934(17)–2.230(4) Å. This is consistent with related
high spin (HS) Co(II) compounds which have reported to have
Co  N(pyridyl) bond lengths of 2.07–2.12 Å and Co  O(amide)
bond lengths of 2.06–2.12 Å.[36,37,40] All complexes show a
distorted octahedral geometry around the central Cot(II) center,
with the relevant bond angles in the range 75.90(12)–
99.52(14)°, deviating from the ideal 90° (Table S3). This
distortion can be ascribed to the restrictions imposed by the
bidentate N-picolinamide ligand. The crystal structures highlight
intramolecular H-bonding between the O(amide) and the ortho
Ar  CH of the same ligand, with bond distances of 2.83–2.86 Å,
intermolecular H-bonding between the S(isothiocyanate) and
the neighboring N  H(amide), with bond distances of 3.32–
3.61 Å, and π–π stacking between the aryl and pyridyl rings of
neighboring molecules, with distances of 3.55–3.87 Å (e.g.
Figure S1).
Scheme 1. Synthetic routes for a) bis(N-picolinamido)cobalt(II) diisothiocya-
nato complexes 1–8, b) bis(N-picolinamido)cobalt(II) dichlorido complex 9
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Figure 3. Molecular structures of complexes 1, 2, 4–10. Displacement ellipsoids are at the 50% probability level for heteroatoms only. Hydrogen atoms and
counterions are omitted for clarity.
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As previously stated, each bis(N-picolinamido)cobalt(II) com-
plex may form five potential (plus two enantiomers) isomers
(Figure 2), however only the trans-trans-trans and cis-trans-cis
isomers have been observed in our solid-state analysis.
Complexes 1, 4, 5, 9 and 10 contain the two X ligands in a trans
arrangement, whereas complexes 2 and 6–8 have the X ligands
in a cis arrangement. In almost all cases, when the aryl ring is
unsubstituted or substituted in the meta position, the X ligands
are positioned in a trans arrangement; whereas substitution in
the ortho or para positions on the aryl ring result in the
corresponding cis complexes.
Of the reported bis(N-picolinamido)cobalt(II) complexes, the
X ligands are described to be in the trans position, though
differences in cis/trans geometry have been noted with
alterations in the axial ligand from aqua[36] to isothiocyanato,[40]
and upon changing the metal ion from cobalt to copper.[40]
However, it appears that the nature of the axial ligand is an
important factor. All previous studies have incorporated
picolinamide ligands with no N-aryl substitutions (similar to
complex 1) and thus this work presents the first study on the
geometric effects of changing the picolinamide ligand sub-
stituents. This work implies that the effect of ligand substituents
on geometry is greater than the effect of the type of axial
ligand or the nature of the cobalt starting material. It is
suggested that the geometries have differing thermodynamic
stabilities depending upon the N-aryl substitution, although the
reason for these differences is unclear. The fact that altering the
position of the same group, e.g. methyl, alters the geometry
implies that steric effects are of greater importance than
electronic effects.
Powder X-ray diffraction (PXRD). PXRD patterns of several
complexes were recorded to allow comparison with the SC-XRD
data (Figure 4). In the solid state, complexes 1, 4 and 5 adopt
the trans geometry whereas complexes 2, 6, 7 and 8 adopt the
cis geometry. All the trans complexes show good agreement
between the experimental and the simulated powder diffrac-
tion patterns, with all of the high intensity peaks from the
simulated pattern present at similar 2θ positions in the
experimental patterns. This confirms that the bulk samples of
these complexes consist of only the trans isomer. For the cis
complexes, the high intensity peaks from the simulated pattern
do appear in the experimental patterns, but some additional
intense peaks are also present in the experimental diffraction
patterns, which cannot be matched to the corresponding
simulated pattern. This could be ascribed to the presence of a
mixture of isomers in the bulk powder sample.[48,51] If the
observed differences are due to the presence of a mixture of
isomers, as this is only observed for cis complexes, this may
imply that the trans complex is the thermodynamic product
and the cis complex (or mixture) is the kinetic product of the
complex synthesis. These mixtures of cis isomers, and stability
of the trans isomers has already been observed in our group,
when N-picolinamide ligands are bound to Ru(III)[48] and Rh(III)[51]
metal centers.
Magnetic properties. Previous bis(picolinamido)cobalt(II)
complexes have been reported to be high spin (HS) with μeff=
4.1 μB.
[52] Our complexes exhibited poor solubility, therefore, the
magnetic behavior was only studied for complex 2 in both
solution and solid state. The solution state studies were
conducted via the Evans NMR method, and complex 2 was
found to have a magnetic moment 4.01 μB at 300 K in d3-
acetonitrile, consistent with a HS system. The magnetic moment
as a function of temperature was also measured by a super-
conducting quantum interference device (SQUID), and 4.36 μB
from 300–75 K before dropping at lower temperatures due to
the effects of zero field splitting (Figure S5). This supported the
solution state data and indicates a HS system.
Cyclic voltammetry. Co(II) complexes can exist as either low
spin (LS) or HS, although octahedral Co(II) systems are more
often HS. However, these d7 systems can have fast transitions
between both spin states, known as spin crossover (SCO). SCO
in Co(II) complexes is uncommon and often gradual or
incomplete; however there are examples of ligand systems
which display abrupt SCO with thermal hysteresis, these ligands
tend to be terpyridine-based systems.[53] In terms of the
spectrochemical series, our complexes have varying ancillary
ligands, whereby X=diisothiocyanato (1–8), dichlorido (9) or
diaqua (10), and so we have assessed if these difference in
crystal field splitting (Δo) energies can affect the complexes
spin properties.
In 2012, Harding and co-workers showed Co(II)-bipyridine
acetylacetone complexes, with a single electron oxidation Epa1,
a small reduction Epc1 and a larger reduction Epc2.
[54] They
concluded the oxidation/reduction is accompanied with a
structural and electronic rearrangement, and the Co(II)-HS state
can go through the following transitions:
CoðIIÞ  HS! CoðIIIÞ  HS! CoðIIIÞ  LS! CoðIIÞ-LS
Cyclic voltammetry measurements have been obtained for
compounds 1–10 and assessed at scan rates between 100–
800 mV/s (Figures S6–S15). At scan rates of 800 mV/s we
observe only one oxidation for Co(II)!Co(III) (Epa1), however, at
slower scan rates of 100 mV/s a second ligand-based oxidation
(Epa2) is observed (e.g. Figure 5A). Notably this second
oxidation is not present for when X=chlorido (9) (Figure 5B)
and suggests this is an ancillary ligand-based oxidation.
Complex 9 shows a quasi-reversible oxidation/reduction, with
Epa1 0.58 V and Epc1 0.43 V. In the case of the diisothiocyanato
Figure 4. Powder X-ray Diffraction (PXRD) patterns for complexes 2 (cis) and
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complexes (1–8), all are non-reversible with weak reduction
energies, which could not be fully identified (Table S4). There
should be two reduction potential for the Co(III)-Co(II) and
ligand-based reduction, however, 3–4 weak peaks are observed.
Though these are not defined enough to calculate the energies,
it is possible they are caused by the HS to LS electronic
rearrangements noted by Harding and co-workers. Complex 10
(X=H2O) has an enhanced reduction at   1.1 V, and due to the
absence of this peak in the other voltammograms, this potential
has been assigned to the aqua ligand (Figure 5C, Table S4).
Antifungal activity: C. albicans is the most prevalent human
fungal pathogen and can cause life-threatening invasive
candidiasis. It is also predicted to contain a variety of anti-
oxidant enzymes.[55] In the saliva, peroxidases can catalyze the
oxidation of thiocyanate (  SCN) by hydrogen peroxide (H2O2) to
hypothiocyanite (  OSCN) and hypothiocyanous acid
(NCSOH),[56,57] These compounds have been shown to inhibit the
viability of C. albicans,[58] and to the best of our knowledge, the
role of the isothiocycanate has not yet been determined.
Whereas, A. fumigatus is the primary cause of the devastating
disease invasive aspergillosis, which is associated with mortality
rates up to 90%. Furthermore, azole resistance has emerged as
a critical issue, and azole-resistant A. fumigatus is to be listed as
a priority fungal pathogen by the World Health Organization.
Previous reports have shown that Co(II) compounds exhibit
moderate inhibition against fungal species, with slight increases
in activity observed against both A. flavus and C. albicans, when
compared to the activities of the free ligands, however, no
selectivity was observed.[23] Compounds 1–10 (at 32 μg ·mL  1)
were screened for their ability to inhibit the growth of the three
common pathogenic species isolated from humans; C. albicans,
C. neoformans and A. fumigatus (Table 2).[59] Complexes with
growth inhibition values >80% were classed as active and
complexes with growth inhibition values in the range 50–80%
were classed as partially active. All of our Co(II) complexes were
completely inactive against C. neoformans, with no observed
growth inhibition (0.0%). The exact reasons underlying the
striking inactivity of these compounds against C. neoformans is
unknown but may be explained in part by the ability of this
organism to form a polysaccharide capsule.[60] Although the
capsule of environmental isolates growing in laboratory media
are much smaller (1–4 μm) and likely more porous than those
grown in capsule-inducing conditions, this capsule may be
sufficient enough to inhibit the penetrance of the compounds
tested and significantly affect their activity.[61–63] Notably, it has
previously been shown that the capsule can protect C. neofor-
mans against other antifungal drugs, such as the polyenes and
glycolipid hydrolase inhibitors.[64,65]
All compounds (except 10) show either partial activity (2, 3,
6–9) or are considered active (1, 4, 5) against C. albicans. The
greatest inhibition was observed with the Co(II) compound
containing an unsubstituted picolinamide ligand (1). However,
changing the ancillary diisothiocyanato ligand in compound 1,
for dichlorido (9) or diaqua (10) significantly decreased the
activity, by >1.9-fold (9) or >3.3-fold (10). Therefore, it can be
concluded that the axial diisothiocyanato ligands are essential
for the antifungal activity of the compounds against C. albicans.
Fungal inhibition studies have been conducted on similar
libraries of picolinamide ligands, however, MIC values of
100 μM and >200 μM were observed against both C. albicans
and C. neoformans, respectively.[66] This suggests the metal-
ligand combination is required for improved fungal inhibition
at lower incubation concentrations.
All compounds (except 2) showed either show partial
activity (50–80%: 1, 3, 4, 6–10) or were considered active
Figure 5. Cyclic voltammograms of compounds; A. complex 1, B. complex 9
and C. complex 10 in dry DMF/0.1 M NBu4PF6; and at a scan rate=100 mV/s.
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(>80%: 5) against A. fumigatus. Interestingly, the activity with
compound 1 was lower against this fungal pathogen, and the
relationship, 1>9>10 no longer applies, suggesting the
diisothiocyanato ligands were not associated with high activity.
Compound 5 (L, R=3’,5’-diMe) displayed the greatest inhibition
of 86.7% and was also highly active against C. albicans (85.9%),
highlighting a broad spectrum of antifungal activity, which is
desirable for drug development. The compounds were also
screened at 16 μg ·mL  1 and remain partially active (Figure S16).
The growth of hyphae is associated with the invasive form of
disease, whereby hyphae penetrate the vasculature and cause
systemic aspergillosis. Treatment with compounds 4–7 had a
demonstrable inhibitory effect on hyphal growth, although
compound 5 demonstrated the most profound inhibition (Fig-
ure 6). The average length of hyphae treated with compound 5
was 91.4% shorter than the hyphal length in the absence of the
compound.
To confirm the selectivity of the compounds toward fungi,
compounds 1–10 were additionally screened against bacterial
strains (E.coli, Klebsiella pneumoniae, Acinetobacter baumannii,
Pseudomonas aeruginosa and S. aureus)[59] and mammalian cell
lines: MIA PaCa-2 (human pancreatic carcinoma), PNT2 (normal
human prostate) and HEK293 (human embryonic kidney).
Promising fungal drugs should not display cytotoxicity toward
host cells. Here, we confirmed that all compounds demonstrate
low toxicity toward bacterial species and are completely non-
toxic toward mammalian cells. This increases the potential of
Table 2. Percentage growth inhibition at 32 μg ·mL  1 against fungal species (C. albicans, C. neoformans, A. fumigatus) and bacterial species (E. coli, K.
pneumoniae, A. baumannii, P. aeruginosa, S. aureus), IC50 values (μM) when screened against mammalian cell lines MIA PaCa-2 and PNT2 (96 h) and CC50
values HEK293 (IC50=50% inhibitory concentration in μM, CC50=50% cytotoxic concentration in μg/mL, FCZ= Fluconazole, ITC= Itraconazole, CS=Colistin-
sulfate, VAN=Vancomycin, TAM=Tamoxifen, CIS=cisplatin).
Fungal Species Bacterial Species Mammalian Cell Lines
























1 86.8 0.0 40.0 4.4 19.1 16.7 0.0 4.4 >100 >100 >32
2 78.6 0.0 32.0 5.2 15.6 11.7 0.0 5.2 >100 >100 >32
3 72.8 0.0 55.7 3.5 14.2 12.8 0.0 3.5 >100 >100 >32
4 81.0 0.0 73.6 0.0 19.2 12.5 0.0 0.0 >100 >100 >32
5 85.9 0.0 86.7 0.0 14.7 8.6 0.0 0.0 >100 >100 >32
6 73.5 0.0 73.3 0.0 16.2 12.8 0.0 0.0 >100 >100 >32
7 72.0 0.0 66.1 0.0 17.5 7.8 0.0 0.0 >100 >100 >32
8 63.5 0.0 54.3 2.1 17.3 11.7 0.0 2.1 >100 >100 >32
9 44.0 0.0 51.5 0.0 16.1 11.8 0.0 0.0 >100 >100 >32
10 26.0 0.0 45.7 3.1 11.2 6.9 0.0 3.1 >100 >100 >32
MIC [μg ·mL  1] MIC [μg ·mL  1] IC50 [μM]
FCZ 0.125 8.0 – – – – – – – – –
ITC – – <2.5[69] – – – – – – – –
CS – – – 0.125 0.25 0.25 0.25 – – – –
VAN – – – – – – – 1.0 – – –
TAM – – 9�2
CIS – – – – – – – – 3.6�0.3 8�1 –
Figure 6. A. The average hyphal length of untreated A. fumigatus and following the treatment with compounds 1–10 after 24 h at 37 °C. B. A representative
image depicting hyphal growth in the presence or absence of 32 μg ·mL  1 compound 5 after 24 h. Hyphal length was measured using ImageJ and results are
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these compounds to be used as antifungal agents and warrants
further drug design and development.
While all of the [(L)2Co(NCS)2] complexes were at least
partially active, the three most active complexes (1, 4 and 5) all
contained the diisothiocyanato ligands in the trans arrange-
ment. Although the differences in percentage growth inhibition
were small, it is unknown if the positioning of the diisothiocya-
nate ligands was associated with the antifungal activity.
However, thiocyanate is a known trans-directing ligand and
previous kinetic studies have been noted for trans and cis
complexes with cobalt.[67,68] In the trans configuration the
isothiocyanates are released more readily, leading to greater
intracellular concentrations, which could lead to the higher
activities of these compounds.
Conclusion
We have synthesized and characterized a range of bis
(picolinamido)cobalt(II) complexes of the type, [(L)2Co(X)2]
0/2+,
where L=a neutral (N,O) picolinamide ligand and X=diisothio-
cyanato (NCS, 1–8), dichlorido (Cl, 9) or diaqua (H2O, 10). SC-
XRD was determined for nine compounds, and PXRD was used
to confirm the cis and trans ligand arrangements. Antifungal
screening highlighted the high activity of these compounds
toward fungi, with several compounds exhibiting growth
inhibitions >80% against both C. albicans and A. fumigatus.
Notably the compounds have low activity against bacterial
strains and no activity against mammalian cells, making them
ideal candidates for further drug development. Compound 5
had the broadest range of antifungal activity and could inhibit
the growth of C. albicans and A. fumigatus by 85.9% and 86.7%,
respectively. Hyphae is associated with the invasive form of
disease, and compound 5 was able to inhibit hyphal growth by
91.4%, compared to the untreated control. Taken together,
these bis(picolinamido)cobalt(II) complexes display antifungal
activity toward clinically relevant fungal pathogens, low
cytotoxicity toward the host, and represent a promising avenue
for the development of novel antifungal drugs.
Experimental Section
General: All ligands and complexes were synthesized under
aerobic conditions. All ligands have previously been reported
and 1H NMR used to confirm successful synthesis.[42–50] All
chemicals were supplied by Sigma-Aldrich Chemical Co., Acros
Organics and Alfa Aesar. Deuterated NMR solvents were
purchased from Sigma-Aldrich Chemical Co. or Acros Organics.
Instrumentation: All NMR spectra were acquired using a Bruker
Advance 300, 400 or 500 MHz spectrometer. Chemical shifts (δ)
are expressed in parts per million (ppm) and reference to the
solvent signal using an internal reference. Mass spectra were
recorded at the University of Leeds Mass Spectrometry Service
on a Bruker Daltonics MicroTOF instrument with electrospray
ionization (ESI) and a photodiode array analyzer. Microanalyses
were acquired either at the University of Leeds Microanalytical
Service using a Carlo Erba 1108 Elemental Analyser or at the
London Metropolitan University Elemental Analysis Service. Infra-
red spectra were acquired on a Perkin-Elmer SpectrumOne FT-IR
spectrometer. Single crystal X-ray diffraction data were collected
using an Agilent (Rigaku) SuperNova X-ray diffractometer fitted
with an Atlas area detector using mirror monochromated Mo-Ka
(λ=0.71073 Å) radiation. X-ray powder diffraction data were
collected using a Bruker AXS D2Phaser diffractometer. Cyclic
voltametric measurements were carried out using Autolab
PGStat 30 potentiostat/galvanostat.
Single Crystal X-Ray Diffraction (SC-XRD): The crystals were
cooled to 120 K using an Oxford Cryosystem low temperature
device.[70] The full dataset was collected and the images
processed using CrysAlisPro program.[71] Structure solution by
direct methods was achieved through the use of SHELXS86,[72]
SHELXL-2014[73] or SHELXT,[74] and the structural model was
refined by full matrix least squares on F2 using SHELX97[75]
interfaced through the program Olex2.[76] Molecular graphics
were plotted, editing of CIFs and construction of tables of bond
lengths and angles were achieved using Olex2. Unless otherwise
stated, hydrogen atoms were placed using idealized geometric
positions (with free rotation for methyl groups), allowed to move
in a “riding model” along with the atoms to which they were
attached, and refined isotropically. Images were made using
Mercury 4.0.[77]
Powder X-ray Diffraction (PXRD): Data collection was carried out
at room temperature using Cu  Ka (λ=1.54184 Å) radiation.
Diffraction patterns were recorded in step-scan mode with a step
size of 0.2° from 5° to 50° (5 s per step) using a 0.1 mm divergent
slit. Experimental data was processed using Diffrac.Eva and
Chekcell. Mercury was used to simulate the powder diffraction
pattern from the single crystal structures.[77]
Cyclic Voltammetry: A single-compartment or a conventional
three-electrode cell was used with a silver/silver chloride
reference electrode (3 M NaCl, saturated AgCl), glassy carbon
working electrode and Pt wire auxiliary electrode. Dimeth-
ylsulfoxide, DMSO, dimethylformamide, DMF or acetonitrile,
MeCN was stored and used over molecular sieves (DMSO and
DMF) or freshly distilled from CaH2 (MeCN). Tetrabutylammonium
hexafluorophosphate [N(C4H9-n)4][PF6] was used as the support-
ing electrolyte. Solutions containing ca. 10  3 M analyte (0.1 M
electrolyte) were degassed by purging with argon, and spectra
were collected with a constant flow of argon. All spectra were
referenced to ferrocene/ferrocenium.
Antifungal Screening (C. albicans and C. neoformans): Both
screening and confirmation HITs were prepared as follows:
Complexes were prepared in DMSO/water to a give a final
concentration of 32 μgmL  1 in 384-well NBS plates. The final
DMSO concentration was at a maximum of 1.0%. Fungi were
cultured for 3 days on yeast extract-peptone dextrose (YPD) agar
at 30 °C. A yeast suspension of 1×106 to 5×106 CFU ·mL  1 (as
determined by OD530) was prepared from 5 colonies. The
suspension was diluted and added to each well of the
compound-containing plates giving a final cell density of fungi
suspension of 2.5×103 CFU ·mL  1 and a total volume of 50 μL.
Fluconazole was used as a positive fungal inhibitor standard and
provided in 4 concentrations, with 2 above and 2 below its MIC
or CC50 value (plated into the first 8 wells of column 23 of the
384-well NBS plates). All the plates were covered and incubated
at 35 °C for 36 h without shaking and conducted in duplicate.
Growth inhibition of C. albicans was determined measuring
absorbance at 630 nm (OD630) and the growth inhibition of C.
neoformans was determined measuring the difference in absorb-
ance between 600 and 570 nm (OD600–570), after the addition of
0.001% resazurin and incubation at 35 °C for an additional 2 h.
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reader. The percentage of growth inhibition was calculated for
each well, using the negative control (media only) and positive
control (fungi without inhibitors) reference cells.
The significance of the inhibition values was determined by
modified Z-scores, calculated using the median and MAD of the
samples (no controls) on the same plate. Samples with inhibition
values�80% and Z-Score >2.5 for either replicate were classed
as actives. Samples with inhibition values in the range 50–80%
and Z-Score >2.5 for either replicate were classed as partial
actives.
Antifungal HIT Confirmation: The MIC was determined as the
lowest concentration at which the growth was fully inhibited,
defined by an inhibition�80% for C. albicans and an inhibition�
70% for C. neoformans. Due to a higher variance in growth and
inhibition, a lower threshold was applied to the data for C.
neoformans. In addition, the maximal percentage of growth
inhibition is reported as DMax, indicating any compounds with
marginal activity. Hits were classified by MIC <16 μg ·mL  1 or
10 μM in either replicate.
Antifungal Growth Inhibition (A. fumigatus): Complexes were
prepared in DMSO to give a final concentration of 32 μg ·mL  1 in
a 96-well plate. The final DMSO concentration was at a maximum
of 1%. A. fumigatus (a kind gift from Dr Alireza Abdolrasouli,
Kings College University Hospital) was cultured on potato
dextrose agar (PDA) for 5 days at 30 °C and ambient humidity.
Spores were harvested using PBS containing 0.01% (v/v) Tween-
80. Each well contained 2×104 CFU ·mL  1 (as determined via a
haemocytometer count) in a total volume of 150 μL RPMI media.
Plates were incubated for 24 h at 37 °C without shaking. Growth
inhibition of A. fumigatus was determined measuring absorbance
at 530 nm (OD530) following the addition of 0.001% resazurin and
incubation at 37 °C for an additional 2 h. Absorbance was
measured using a Flexstation III multimode plate reader (Molec-
ular Biosciences). The percentage of growth inhibition was
calculated for each well, using the negative control (media only)
and positive control (fungi without inhibitors) on the same plate.
Images were obtained using an EVOS XL Core Imaging System
(ThermoFisher Scientific) using a x40 objective. Hyphal growth
was measured using ImageJ and is representative of 100 fungal
cells. Significance was determined via one-way ANOVA with
Dunnett’s multiple comparisons.
Antibacterial Screening: Both screening and confirmation HITs
were prepared as follows: Complexes were prepared in DMSO to
a give a final concentration of 32 μg ·mL  1 in 384-well non-
binding surface (NBS) plate. The final DMSO concentration was at
a maximum of 1.0%. All bacteria were cultured in Cation
adjusted Mueller Hinton Broth (CAMHB) at 37 °C overnight. A
sample of each culture was diluted 40-fold in fresh broth and
incubated at 37 °C for 1.5–3 h. The resultant mid-log phase
cultures were diluted (CFU ·mL  1 measured by OD600), then
added to each well of the compound containing plates, giving a
cell density of 5×105 CFU ·mL  1 and a total volume of 50 μL.
Colistin and vancomycin were used as positive bacterial inhibitor
standards for Gram-negative and Gram-positive bacteria, respec-
tively. Each standard was provided in 4 concentrations, with 2
above and 2 below its MIC or CC50 value (plated into the first 8
wells of column 23 of the 384-well NBS plates). All plates were
covered and incubated at 37 °C for 18 h without shaking and
conducted in duplicate. Inhibition of bacterial growth was
determined by measuring absorbance at 600 nm (OD600), using a
Tecan M1000 Pro monochromator plate reader. The percentage
of growth inhibition (%) was calculated for each well, using the
negative control (media only) and positive control (bacteria
without inhibitors) reference cells.
The significance of the inhibition values was determined by
modified Z-scores, calculated using the median and MAD (mean
absolute deviation) of the samples (no controls) on the same
plate. Samples with inhibition values�80% and Z-Score >2.5 for
either replicate were classed as actives. Samples with inhibition
values in the range 50–80% and Z-Score >2.5 for either replicate
were classed as partial actives.
Antibacterial HIT confirmation: The percentage of growth
inhibition was calculated as stated above and the MIC deter-
mined as the lowest concentration at which the growth was fully
inhibited, defined by an inhibition�80%. In addition, the
maximal percentage of growth inhibition is reported as DMax,
indicating any compounds with partial activity. HITs were
classified by MIC <16 μg ·mL  1 or 10 μM in either replicate.
Mammalian Cytotoxicity Screening
MIA PaCa-2 and PNT2: Cellular assays were conducted using
human pancreatic carcinomas (MIA PaCa-2) and human prostate
cells (PNT2). All cell lines were routinely maintained as mono-
layer cultures in appropriate complete medium in either T-25 or
T-75 flasks at 37 °C and 5% CO2. All cell lines were culture in
Dulbecco’s modified eagle medium (DMEM) medium containing
10% foetal calf serum supplemented with sodium pyruvate
(1 mM) and L-glutamine (2 mM). Prior to chemosensitivity
studies, cell monolayers were passaged using Trypsin-EDTA and
diluted to a concentration of 1×104 cells ·mL  1. All assays were
conducted using 96-well plates, in which 100 μL of the cell
suspension was added to each well and incubated for 24 h at
37 °C and 5% CO2. After 24 h, 100 μL of the drug dilutions
(100 mM stock in DMSO) in media were added to the plates
(columns 3–12; column 1 contains media; column 2 contains
100% cells), and then incubated for a further 96 h at 37 °C and
5% CO2. After 96 h, 20 μL MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, 5 mg ·mL  1) was added to each
well and incubated for 3 h at 37 °C and 5% CO2. All solutions
were then removed via pipette and 150 μL of DMSO added to
each well to dissolve the purple formazan crystals. After mixing
well, the absorbance of each well was measured at 540 nm using
a ThermoFisher Multiskan FC spectrophotometer microplate
reader. Results were plotted on a logarithmic scale, and the half
maximal inhibitory concentration (IC50) determined from dupli-
cate of triplicate repeats and reported as an IC50� Standard
Deviation (SD).
HEK293: Cells were counted manually in a Neubauer hemocy-
tometer and then plated in the 384-well plates containing the
compounds to give a density of 6×103 cells ·well  1 in a final
volume of 50 μL. DMEM supplemented with 10% FBS was used
as growth media and the cells were incubated together with the
compounds for 20 h at 37 °C in 5% CO2. Tamoxifen was used as a
positive cytotoxicity standard. The cytotoxic drug was provided
at four concentrations, with two above and two below the CC50
value. All experiments were performed in duplicate. Cytotoxicity
was measured by fluorescence with excitation at 560 nm and
emission at 590 nm (F560/590), after addition of 5 μL of resazurin
(25 μg ·mL  1) and incubation for a further 3 h at 37 °C in 5% CO2.
The fluorescence intensity was measured using a Tecan M1000
Pro monochromator plate reader, using automatic gain calcu-
lation CC50 were calculated by curve fitting the inhibition values
against log(concentration) using sigmoidal dose-response func-
tion, with variable fitting values for bottom, top and slope. The
maximal percentage of cytotoxicity is reported as DMax, indicating
any compounds with partial cytotoxicity. The curve fitting was
implemented using Pipeline Pilot’s dose-response component.
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(low DMax value) or samples with CC50 values above the maximum
tested concentration. Cytotoxic samples were classified by CC50�
32 μg ·mL  1 in either replicate.
Synthesis and Characterization: A functionalized picolinamide
ligand (2 eq.) in ethanol (10 mL) was added to a solution of
cobalt(II) nitrate hexahydrate (1 eq.) in distilled water (5 mL) and
stirred at 50 °C for 15 min. Potassium thiocyanate (2 eq.) in
distilled water (5 mL) was added dropwise and the mixture was
stirred at 50 °C for 2 h to yield a dark pink solution. Slow
evaporation of solvent from the reaction mixture yielded pure
products.
Complex 1. Dark pink crystals. Yield: 0.175 g, 0.337 mmol, 73%.
1H NMR: (d6-DMSO, 300.13 MHz, 300.0 K): δ 10.54 (br. s, 2H, NH),
8.68 (br. s, 2H, pyridyl CH), 8.01 (br. s, 4H, pyridyl CH), 7.88 (br. s,
4H, aryl CH), 7.62 (br. s, 2H, pyridyl CH), 7.26 (br. s, 4H, aryl CH),
7.04 (br. s, 2H, aryl CH); Analysis calculated for C26H20N6O2S2Co: C
54.64, H 3.53, N 14.70%, Found: C 54.45, H 3.50, N 15.10%; ES MS
(+) (CH3CN): m/z 513.07 [M-NCS
+ ]; IR (cm  1): 3295 (br. w, NH),
3054 (w, CH), 2080 (s, CN), 1632 (m, CO), 1605 (m, CO), 1551 (m),
1341 (m), 1261 (m), 1019 (m), 903 (m), 747 (s), 706 (s), 508 (m).
Complex 2. Pink crystals. Yield: 0.228 g, 0.382 mmol, 91%. 1H
NMR: (d6-DMSO, 300.13 MHz, 300.0 K): δ 10.21 (br. s, 2H, NH), 8.70
(br. s, 2H, pyridyl CH), 8.12 (br. s, 2H, pyridyl CH), 8.03 (br. s, 2H,
pyridyl CH), 7.82 (br. s, 2H, aryl CH), 7.64 (br. s, 2H, pyridyl CH),
7.22 (br. s, 4H, aryl CH), 7.07 (br. s, 2H, aryl CH), 2.28 (br. s, 6H,
CH3). Analysis calculated for C28H24N6O2S2Co: C 56.09, H 4.03, N
14.02%. Analysis found: C 55.98, H 4.21, N 13.97%. ES MS (+)
(CH3CN): m/z 541.10 [M-NCS
+ ]. IR (cm  1): 3225 (br. w, NH), 3066
(w, CH), 2872 (w, CH), 2069 (s, CN), 1632 (m, CO), 1589 (m, CO),
1523 (s), 1459 (m), 1304 (w), 997 (w), 917 (w), 747 (s), 692 (m),
595 (w).
Complex 3. Purple solid. Yield: 0.248 g, 0.395 mmol, 94%. 1H NMR
(d6-DMSO, 500.23 MHz, 300.1 K): δ 10.20 (br. s, 2H, NH), 8.63 (br. s,
2H, pyridyl CH), 8.05 (br. s, 2H, pyridyl CH), 7.96 (br. s, 2H, aryl
CH), 7.55 (br. s, 2H, pyridyl CH), 7.48 (br. s, 2H, pyridyl CH), 6.99
(br. s, 2H, aryl CH), 6.95 (br. s, 2H, aryl CH), 2.18 (br. s, 6H, methyl
CH3), 2.09 (br. s, 6H, methyl CH3); Analysis calculated for
C30H30N6O2S2Co: C 57.41, H 4.50, N 13.39%, Found: C 57.50, H 4.64,
N 13.24%; ES MS (+) (CH3CN: m/z 569.13 [M-NCS
+ ]; IR (cm   1):
3264 (br. w, NH), 3068 (w, CH), 2915 (w, CH), 2070 (s, CN), 1633
(m, CO), 1589 (m, CO), 1531 (s), 1471 (m), 1304 (w), 1264 (w),
1017 (w), 780 (m), 694 (m), 576 (w).
Complex 4. Pink crystals. Yield: 0.246 g, 0.410 mmol, 98%. 1H
NMR (d6-DMSO, 300.13 MHz, 300.0 K): δ 10.46 (br. s, 2H, NH), 8.68
(br. s, 2H, pyridyl CH), 8.03 (br. s, 4H, pyridyl CH), 7.71 (br. s, 2H,
aryl CH), 7.64 (br. s, 4H, aryl and pyridyl CH), 7.16 (br. s, 2H, aryl
CH), 6.89 (br. s, 2H, aryl CH), 2.24 (br. s, 6H, CH3); Analysis
calculated for C28H24N6O2S2Co: C 56.09, H 4.03, N 14.02%, Found: C
55.97, H 4.02, N 13.95%. ES MS (+) (CH3CN): m/z 541.10 [M-NCS
+ ];
IR (cm  1): 3255 (br. w, NH), 3067 (w, CH), 2918 (w, CH), 2083 (s,
CN), 1630 (s, CO), 1587 (m, CO), 1551 (s), 1438 (m), 1261 (w), 1020
(w), 781 (m), 682 (m), 645 (m).
Complex 5. Dark pink crystals. Yield: 0.233 g, 0.372 mmol, 89%.
1H NMR (d6-DMSO, 500.23 MHz, 300.1 K): δ 10.27 (br. s, 2H, NH),
8.60 (br. s, 2H, pyridyl CH), 7.96 (br. s, 4H, pyridyl CH), 7.45 (br. s,
6H, aryl and pyridyl CH), 6.67 (br. s, 2H, aryl CH), 2.12 (br. s, 12H,
CH3); Analysis calculated for C30H28N6O2S2Co: C 57.41, H 4.50, N
13.39%. Found: C 57.41, H 4.60, N 13.60%; ES MS (+) (CH3CN): m/z
569.13 [M-NCS+ ]; IR (cm  1): 3263 (br. w, NH), 3099 (w, CH), 2912
(w, CH). 2098 (s, CN), 1632 (m, CO), 1557 (m, CO), 1433 (m), 1309
(w), 1020 (w), 824 (m), 746 (m), 678 (s).
Complex 6. Pink crystals. Yield: 0.174 g, 0.291 mmol, 69%. 1H
NMR (d6-DMSO, 300.13 MHz, 300.0 K): δ 10.47 (br. s, 2H, NH), 8.68
(br. s, 2H, pyridyl CH), 8.03 (br. s, 4H, pyridyl CH), 7.75 (br. s, 4H,
aryl CH), 7.61 (br. s, 2H, pyridyl CH), 7.08 (br. s, 4H, aryl CH), 2.20
(br. s, 6H, CH3); Analysis calculated for C28H26N6O3S2Co · H2O: C
54.45, H 4.24, N 13.79%; Found: C 54.79, H 4.01, N 13.79%; ES MS
(+) (CH3CN): m/z 541.10 [M-NCS
+ ]; IR (cm  1): 3261 (br. w, NH),
3085 (w, CH), 2081 (s, CN), 1630 (m, CO), 1586 (m, CO), 1529 (m),
1260 (w), 1020 (w), 808 (m), 751 (m), 687 (m), 596 (m), 509 (s).
Complex 7. Purple crystals. Yield: 0.127 g, 0.184 mmol, 44%. 1H NMR
(d6-DMSO, 500.57 MHz, 299.3 K): δ 10.45 (br. s, 2H, NH), 8.66 (br. s,
2H, pyridyl CH), 8.07 (br. s, 2H, pyridyl CH), 8.01 (br. s, 2H, pyridyl
CH), 7.60 (br. s, 2H, pyridyl H), 7.19 (br. s, 4H, aryl CH), 6.21 (br. s, 2H,
aryl CH), 3.60 (br. s, 6H, OCH3); Analysis calculated for
C30H28N6O6S2Co: C 52.10, H 4.08, N 12.15%; Found: C 51.97, H 4.09, N
12.01%; ES MS (+) (CH3CN): m/z 633.11 [M-NCS
+]; IR (cm  1): 3207
(br. w, NH), 3084 (w, CH), 2963 (w, CH), 2072 (s, CN), 1612 (m, CO),
1555 (m, CO), 1318 (m), 1158 (s), 1065 (m), 832 (m), 752 (m), 675
(m), 640 (m).
Complex 8. Pink crystals. Yield: 0.146 g, 0.231 mmol, 55%. 1H NMR
(d6-DMSO, 500.57 MHz, 299.3 K): δ 10.47 (br. s, 2H, NH), 8.68 (br. s,
2H, pyridyl CH), 8.09 (br. s, 2H, pyridyl CH), 8.01 (br. s, 2H, pyridyl
CH), 7.78 (br. s, 4H, aryl CH), 7.61 (br. s, 2H, pyridyl CH), 6.88 (br. s,
4H, aryl CH), 3.49 (br. s, 6H, OCH3); Analysis calculated for
C28H24N6O4S2Co: C 53.25, H 3.83, N 13.31%. Analysis found: C 53.33, H
3.70, N 13.24%; ES MS (+) (CH3CN): m/z 573.09 [M-NCS
+]; IR (cm  1):
3300 (br. w, NH), 3092 (w, CH), 2837 (w, CH), 2081 (s, CN), 1626 (m,
CO), 1585 (m, CO), 1537 (m), 1508 (m), 1186 (m), 1020 (m), 827 (m),
751 (m), 550 (m), 524 (m).
Complex 9. A functionalized picolinamide ligand (2 eq.) in ethanol
(10 mL) was added to a solution of cobalt(II) chloride hexahydrate
(1 eq.) in ethanol (10 mL) and stirred at 50 °C for 2 h to yield an
orange suspension. The solid was filtered, washed with ethanol and
dried to yield pure product. Orange crystals. Yield: 0.212 g,
0.403 mmol, 96%. 1H NMR: (d6-DMSO, 300.13 MHz, 300.0 K) δ 10.59
(br. s, 2H, NH), 8.74 (br. s, 2H, pyridyl CH), 8.10 (br. s, 4H, pyridyl CH),
7.91 (br. s, 4H, aryl CH), 7.68 (br. s, 2H, pyridyl CH), 7.33 (br.s, 4H,
aryl CH), 7.10 (br.s, 2H, aryl CH). Analysis calculated for
C24H20Cl2N4O2Co: C 54.77, H 3.83, N 10.65%. Analysis found: C 54.86,
H 3.65, N 10.62%. ES MS (+) (CH3CN): m/z 490.06 [M–Cl
+]. IR (cm  1):
3248 (w, NH), 3092 (w, ArCH), 1630 (m, CO), 1609 (m, CO), 1586 (m),
1558 (m), 1502 (m), 1447 (m), 1347 (m), 1264 (w), 1022 (w), 904 (w),
758 (s), 681 (s), 515 (m).
Complex 10. A functionalized picolinamide ligand (2 eq.) in
ethanol (10 mL) was added to a solution of cobalt(II) chloride
hexahydrate (1 eq.) in distilled water (5 mL) and stirred at 50 °C
for 15 min. Potassium iodide (2 eq.) in distilled water (5 mL) was
added dropwise and the mixture was stirred at 50 °C for 2 h to
yield an orange solution. Slow evaporation of solvent from the
reaction mixture yielded pure product. Orange crystals. Yield:
0.304 g, 0.408 mmol, 97%. 1H NMR (d6-DMSO, 300.13 MHz,
300.0 K): δ 10.54 (2H, NH), 8.68 (br. d, 2H, pyridyl CH), 8.11 (br. s,
4H, pyridyl CH), 7.86 (br. s, 4H, aryl CH), 7.62 (br.s, 2H, pyridyl
CH), 7.25 (br. s, 4H, H pyridyl CH), 7.06 (br. s, 2H, pyridyl CH);
Analysis calculated for C24H24I2N4O2Co ·3H2O: C 36.07, H 3.78, N
7.01%; Found: C 35.85, H 3.18, N 6.66% ES MS (+) (CH3CN:) m/z
582.00 [M-(2H2O+ I)]
+; IR (cm   1): 3315 (br. m, OH), 3254 (m, NH),
3084 (w, ArCH), 1626 (m, CO), 1602 (m, CO), 1582 (m), 1547 (m),
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FULL PAPERS
Bis(N-picolinamide)cobalt(II)
complexes containing trans isothio-
cyanate ligands are reported to have
significantly enhanced activity
toward fungal species, when
compared the cis complexes. They
display >80% growth inhibition of
fungal strains and no reported
toxicity toward bacterial species or
mammalian cells.
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